Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06254612 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by Sirtsei Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 456
- Enrollment target
- 20
- Study locations
NCT06254612 is a Phase 2 study of Major Depressive Disorder that is actively recruiting participants, run by Sirtsei Pharmaceuticals. The registered enrollment target is 456 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06254612, a Phase 2 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Sirtsei Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 456 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SP-624
Study Locations (20)
California
- Clinical Innovations - Bellflower
- Sun Valley Research Center - Imperial
- Sunwise Clinical Research - Lafayette
- Synergy San Diego - Lemon Grove
- Excell Research - Oceanside
- CiTrials - Riverside
- Collaborative Neuroscience Research - Torrance
- Next Level Clinical Trials - West Covina
Florida
- Clinical Neuroscience Solutions - Jacksonville
- Accel Clinical - Lakeland
- Segal Trials - Lauderhill
- Segal Trials - Miami Lakes - Miami Lakes
- Clinical Neuroscience Solutions - Orlando
- DMI Research - Pinellas Park
Arizona
- IMA Clinical Research - Phoenix
- Noble Clinical Research - Tucson
Arkansas
- SanRo Clinical Research Group - Bryant
Colorado
- MCB Clinical Research Centers - Colorado Springs
Georgia
- Accelerated Enrollment Solutions - Atlanta
Idaho
- Velocity Clinical Research - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06254612
The ClinicalTrials.gov registry entry for NCT06254612 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (22% higher). The listed sponsor is Sirtsei Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06254612 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06254612 about?
NCT06254612 is a clinical study titled "A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder". This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
What is the current status of trial NCT06254612?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 456 participants. The study started on 2024-03-25. Estimated completion is 2026-07-01.
What conditions does trial NCT06254612 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT06254612?
The interventions under investigation include: Placebo (DRUG), SP-624 (DRUG).
Who is sponsoring clinical trial NCT06254612?
This trial is sponsored by Sirtsei Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06254612 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.